Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
WADA 2026: already covered by S5 at all times as a specified substance. The 2027 List adds the name as an example, effective 1 January 2027; this is not a new permission-to-prohibition change. [1] [2] [3]
2026 and 2027 List, S5, printed p.12; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical and pharmacological context
The reviewed September 2026 US Kerendia label describes a nonsteroidal mineralocorticoid-receptor antagonist. Indications include cardiorenal risk reduction in adults with type-2-diabetes-associated chronic kidney disease, urinary albumin-to-creatinine ratio reduction in type-1-diabetes-associated CKD, and specified heart-failure outcomes in adults with LVEF at least 40%. [4]
- The cited country-specific product information does not establish worldwide authorization or current supply.
Health concerns
High potassium, low blood pressure, low sodium and worsening kidney function in heart-failure patients are important concerns. Strong CYP3A4 inhibitors are contraindicated. [4]
- Selected warnings, not a complete contraindication or interaction list. Patient-label evidence does not establish athlete safety.
Additional anti-doping conditions
When a prohibited diuretic or masking agent is detected with formoterol, salbutamol, cathine, ephedrine, methylephedrine or pseudoephedrine, S5 has an additional TUE requirement even below the usual threshold. The note expressly excludes qualifying carbonic-anhydrase-inhibitor eye administration and local dental felypressin. It is not a dosing or test-clearance rule. [1] [2]
- A prescription or medical indication is not itself a TUE approval.
What the clinical endpoint means
The label describes FINE-ONE as a randomized, double-blind, placebo-controlled study in 242 adults with type-1-diabetes-associated CKD. Its principal outcome was change in urinary albumin-to-creatinine ratio over six months. Reduction of this surrogate is not direct demonstration of fewer kidney-failure events in that study. [4]
- Clinical disease populations and endpoints do not establish performance enhancement in healthy athletes.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S5 p.12
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S5 p.12
- UKAD 2027 Prohibited List: Summary of Changes ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Additional examples
- Kerendia (finerenone) tablets (DailyMed) ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Clinical Studies 14.2, FINE-ONE · Indications; clinical pharmacology or SmPC sections 4.1 and 5.1 · Warnings, precautions and adverse reactions
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.